FREA.F FRESENIUS SE+CO. ADR 1/4

Healthcare Health Care Providers & Services Frankfurt Exchange
13.10 EUR
Close of Nov 12, 2026
8.60 13.20
Market cap
EUR 29.5B
P/E
18.5x
P/B
1.43x
ROE
7.7%
Dividend yield
2.32%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is FREA.F undervalued?

Graham number
Price13.10
Graham value12.11
Premium8.2%

FREA.F trades 8.2% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

FRESENIUS SE+CO. ADR 1/4 fundamental analysis

No fundamental analysis for FRESENIUS SE+CO. ADR 1/4 yet.

FRESENIUS SE+CO. ADR 1/4 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About FRESENIUS SE+CO. ADR 1/4

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. I…

Full company profile